Summary: Poly[2-methacryloyloxyethyl phosphorylcholine-co-n-butyl methacrylate]s (PMBs) are watersoluble solid copolymers of 2-methacryloyloxyethyl phosphorylcholine (MPC) and n-butyl methacrylate with a molecular weight of 30,000 (PMB50T) or 100,000 (PMB100T). Here, we characterized the solubilizing properties of PMBs using miconazole (MCZ), vidarabine (Ara-A) and griseofulvin (GRF), which are class 2, 3 and 4 compounds, respectively, in the Biopharmaceutics Classification System (BCS). Moreover, we evaluated the enhancement of gastric absorption of GRF dissolved in PMB solutions and the toxicity of PMBs in rats. PMB50T solution dramatically increased the solubility of GRF and MCZ compared with Ara-A, and these drugs became more soluble as the concentration of PMB50T was increased. The solubility of GRF in 10% PMB solutions was higher than with any other tested aqueous solubilizer. When a solution of GRF (20 mg/10 mL/kg) in 10% PMB was orally administered to rats, GRF absorption was greatly increased compared with that following administration of a suspension in water or Gelucire. After repeated oral administration of PMBs once daily for 14 successive days, no organ lesions or changes in biochemical parameters were observed. Thus, the polymers are expected to be useful and safe solubilizers and oral absorption enhancers for poorly soluble lipophilic drugs.
Introduction
The cell membrane in living organisms is mainly composed of phospholipid molecules, which have hydrophobic alkyl chains and hydrophilic polar groups, such as phosphorylcholine. 2-Methacryloyloxyethyl phosphorylcholine ¤MPC¥ was designed as an artificial phospholipid, 1¥ and recently, several kinds of MPC-containing polymers have been developed. Because the chemical structure of MPC polymers resembles that of the cell membrane, materials whose surfaces are coated with MPC polymers are not recognized as foreign substances. In addition, there is little interaction, such as nonspecific protein absorption, between these polymers and biomaterials.
2,3¥ Therefore, the polymers are widely applied as biocompatible materials in chip devices, 4¥ catheters, 5¥ soft contact lenses 6¥ and artificial joints in the biomedical field.
7¥
PolyªMPC-co-n-butyl methacrylate«s ¤PMBs¥ ¤PURE-BRIGHT MB; NOF Corporation¥, which are copolymers consisting of MPC as a hydrophilic unit and n-butyl methacrylate as a hydrophobic unit ¤Fig. 1A¥, are watersoluble solid polymers of M.W. 30,000 ¤PMB50T¥ or M.W. 100,000 ¤PMB100T¥. The polymers are used commercially as solubilizers for hydrophobic drugs, such as the antitumor agent paclitaxel, working via hydrophobic interaction with the n-butyl methacrylate unit. 8¥ The Biopharmaceutics Classification System ¤BCS¥ 9,10¥ categorizes drugs into four classes according to their solubility and permeability. In this classification, high-solubility, highpermeability drugs; low-solubility, high-permeability drugs; high-solubility, low-permeability drugs; and low-solubility, low-permeability drugs are defined as class 1, class 2, class 3 and class 4, respectively. In the case of class 2 and class 4 compounds, poor solubility is often a limiting factor in their absorption from the gastrointestinal tract.
11,12¥ Therefore, various solubilizing methods, such as solid dispersions, 13¥ water-soluble carriers 14®16¥ or surfactants, 17¥ have been developed to increase the solubility of such drugs.
The purpose of the present study was to characterize the solubilizing properties of PMB solutions and to examine whether PMBs enhance gastrointestinal absorption of drugs. We initially selected miconazole ¤MCZ¥, vidarabine ¤Ara-A¥ and griseofulvin ¤GRF, Fig. 1B¥ as representative BCS class 2, class 3 and class 4 compounds, respectively, 10¥ and evaluated the solubility of these drugs in PMB solutions. Then, the solubilizing ability of PMB solutions was compared with those of other solubilizers, using GRF as a model drug. Moreover, the enhancing effects of 10% PMB polymer solution and 10% Gelucire suspension on GRF absorption in rats were compared. Further, the toxicity of 10% PMB solutions in repeatedly dosed rats was evaluated by means of pathological and serum biochemical studies.
Materials and Methods
Test materials: PMB50T and PMB100T were gifts from NOF Corporation ¤Tokyo, Japan¥. Gelucire 44/14 was obtained from Gattefossé Canada Inc. ¤Montreal, Quebec¥. Griseofulvin, polyoxyethylene hydrogenated castor oil ¤HCO-60¥, polyethyleneglycol 400 ¤PEG 400¥, dimethyl sulfoxide ¤DMSO¥ and dimethylformamide ¤DMF¥ were purchased from Wako Pure Chemical Industries ¤Osaka, Japan¥. Pluronic F-68 polyol powder and Polysorbate 60 were purchased from MP Biomedicals ¤Irvine, CA¥ and Alfa Aesar ¤Waldhill, MA¥, respectively. A human colon adenocarcinoma cell line, Caco-2, was obtained from the American Type Culture Collection ¤Rockville, MD¥. Dulbeccoös modified Eagleös medium ¤DMEM¥, nonessential amino acids, penicillin, streptomycin, gentamycin, and Hanksö balanced salt solution ¤HBSS¥ were all from Invitrogen Corp. ¤Carlsbad, CA¥. Fetal bovine serum ¤FBS¥ was obtained from ICN Biomedicals, Inc. ¤Osaka, Japan¥, and type-I collagen solution was from Nitta Gelatin ¤Osaka, Japan¥.
Animals: Experimental procedures using animals were performed according to the Guidelines for the Care and Use of Laboratory Animals at the Takasaki University of Health and Welfare and approved by the Committee of Ethics of Animal Experimentation of the university. Specificpathogen-free male Wistar rats ¤weight, 190®215 g¥ were purchased at eight weeks of age from SLC Japan ¤Hamamatsu, Japan¥ and housed in cages in an animal room kept under controlled conditions ¤temperature of 23 + 3ôC, humidity of 50 + 20%, lighting for 12 hours¥. The rats were fed a pelleted diet ¤CA-1, Clea Japan Inc., Tokyo¥ and provided with water ad libitum.
Solubility study: Excess amounts of MCZ, Ara-A or GRF were added in 1 mL of distilled water ¤DW¥ and mixed by vortexing. The mixture was then kept at room temperature with stirring for 2 hours. The sample was centrifuged at 67 ' g for 10 minutes to remove undissolved drugs. The drug concentration in the supernatant was determined from the absorbance at 254 nm for MCZ, at 259 nm for Ara-A or at 290 nm for GRF using a spectrophotometer ¤Wallac 1420 ARVO MX/Light, Perkin Elmer, Waltham, MA¥, and was used as a measure of solubility. Relative solubility was estimated as the ratio of the solubility of a drug in PMB solution ¤0.1%, 1% or 10%¥ to the solubility in 10% DMSO solution. In addition, the solubilities of GRF in 0.1%, 1% or 10% Polysorbate or Pluronic; 10% DMSO or Gelucire; 1% lecithin, HCO60 or Ç-cyclodextrin; and saline were measured as described above.
Transcellular transport study: The cultivation of Caco-2 cells was performed as described previously.
18,19¥
Caco-2 cells were cultured in DMEM containing 10% FBS, 1% nonessential amino acids, 100 units/mL penicillin, 0.1 mg/mL streptomycin, and 25 µg/mL gentamycin in a humidified atmosphere of 5% CO 2 at 37ôC. Cells at a passage number of 47 were used. Caco-2 cells were routinely grown to confluence in 75-cm 2 tissue culture dishes and seeded into Transwell inserts coated with type-I collagen ¤pore size: 0.4 µm, diameter: 12 mm, Costar, Cambridge, MA¥. The cells were seeded at a density of 2 ' 10 5 cells/cm 2 and monolayers were formed after culturing for 3 weeks. The integrity of the cell layer was evaluated by measurement of transepithelial electrical resistance ¤TEER¥ with Millicell-ERS equipment ¤Nihon Millipore, Tokyo¥. The TEER of the monolayers was measured before and after each transport experiment, and monolayers with a TEER of more than 350 Å&cm 2 were used for the transepithelial transport experiments. HBSS solutions ª137 mM NaCl, 5.37 mM KCl, 5.55 mM D-glucose, 1.26 mM CaCl 2 , 0.441 mM KH 2 PO 4 , 0.811 mM MgSO 4 , 0.337 mM Na 2 HPO 4 , 4.17 mM NaHCO 3 , 10.0 mM 2-ª4-¤2-hydroxyethyl¥-1-piperazinyl« ethanesulfonic acid ¤HEPES¥ for pH 7.4 or 10.0 mM 2-¤N-morpholino¥ethanesulfonic acid ¤MES¥ for pH 6.0« were used for the transcellular transport study. Monolayers of Caco-2 cells were gently rinsed twice with saline. To measure the apical-to-basolateral permeability, 1.5 mL of HBSS ¤pH 7.4, 37ôC¥ was added to the basolateral chamber of the Transwell insert and then 0.5 mL of the test solution ¤HBSS, pH 6.0, 37ôC¥ containing 300 µM GRF was added to the apical side. After the desired incubation time at 37ôC, the basolateral solution was collected, and replaced with an equal volume of HBSS ¤pH 7.4, 37ôC¥. The permeability coefficient was calculated from the linear portion of permeability versus time plots using the following equation: P app © dQ/dt/A/C 0 , where dQ/dt is the initial permeation rate across the Caco-2 cell monolayer, A is the surface area of the filter, and C 0 is the initial concentration of the solution on the apical side.
Pharmacokinetic study: Rats were fasted for 12 hours before experiments. GRF was suspended in DW or 10% Gelucire solution and dissolved in 10% PMB50T or PMB100T solution. Each GRF suspension or solution was orally administered to rats at a dose of 20 mg/10 mL/kg. For the intravenous injection study, GRF was dissolved in DMF:PEG400:DW ¤1:1:1, v/v/v¥, and rats were administered 20 mg/mL/kg of GRF via the caudal vein. Blood samples were withdrawn from the jugular vein of rats with a heparinized syringe at designated times under anesthesia induced with diethyl ether; the samples were centrifuged at 1,700 ' g for 10 minutes to obtain plasma. Plasma ¤50 µL¥ was deproteinized with an equal volume of acetonitrile, followed by centrifugation at 15,000 ' g for 10 minutes at 4ôC. The concentration of GRF in the supernatant was determined by high-performance liquid chromatography ¤HPLC¥ using a constant-flow pump ¤Shimadzu LC-10AT¥, a UV detector ¤Shimadzu SPD-10A¥, an automatic sample injector ¤Shimadzu SIL-10A¥ and an integrator ¤Shimadzu C-R7APlus¥. The analytical column was a COSMOSIL 5C18-AR-II ¤4.6 ' 150 mm, Nacalai Tesque, Kyoto, Japan¥. The flow rate of the mobile phase, which consisted of 10 mM phosphate buffer ¤pH 4.0¥-acetonitrile ¤1:1, v/v¥ solution, was 1 mL/min. The column temperature was 40ôC and the effluent was monitored at 290 nm. The maximum plasma concentration ¤C max ¥ and time to C max ¤T max ¥ were determined directly from observed data. The area under the plasma concentration-time curve from 0 to 8 hours ¤AUC 0®8hr ¥ was estimated by means of the linear trapezoidal method. The elimination constant ¤ke¥ was estimated by a nonlinear least-squares analysis using at least three observed terminal points in a model-independent moment program ¤http://www.pharm.kyoto-u.ac.jp/byoyaku/ Kinetics/download.html¥. 20¥ AUC 0®W was calculated by adding AUC 0®8hr to AUC 8hr®W estimated using the ke value.
Safety assessment: Rats were orally administered 10% PMB50T or PMB100T solution ¤10 mL/kg/day¥ once daily for 14 successive days. Twenty-four hours after the last administration, the rats were euthanized by exsanguination from the abdominal aorta under ether anesthesia. The kidneys, liver, small intestine and large intestine were quickly removed, fixed in 10% neutral buffered formalin, processed routinely and embedded in paraffin. Paraffin sections then were prepared, stained with hematoxylin and eosin, and examined microscopically. Sera were separated and subjected to the measurement of serum creatinine ¤CRE¥, blood urea nitrogen ¤BUN¥, alkaline phosphatase ¤ALP¥, aspartate aminotransferase ¤AST¥ and alanine aminotransferase ¤ALT¥ using an automated analyzer ¤Type 7350, Hitachi, Japan¥.
Statistical analysis: For the solubility test, experiments were performed in duplicate and mean values were calculated. For transcellular transport, pharmacokinetic and toxicity studies, data were expressed as mean + S.E.M. Statistical analysis was performed using Studentös t test. The difference between means was considered to be significant when the p value was less than 0.05.
Results
Solubilizing property of PMBs with MCZ, Ara-A and GRF: The relative solubilities of MCZ, Ara-A and GRF in 0.1, 1.0 and 10% PMB50T solutions versus 10% DMSO solution are shown in Table 1 . The solubilities of all drugs increased as the concentration of the PMB was increased. The solubility of MCZ in 0.1, 1.0 or 10% PMB50T solution was 5, 96 or 1058 times higher than that in 10% DMSO solution, respectively. The solubility of GRF in PMB50T solution at the same concentrations was 0.5, 1.8 or 9.3 times that in 10% DMSO, respectively. On the other hand, the solubility of Ara-A was less effectively enhanced, being 1.2, 1.6 or 1.8 times that in 10% DMSO solution.
The absolute solubility of GRF in 10% PMB50T or PMB100T solution was compared with those in other solubilizers ¤Fig. 2¥. Solubility in 0.1% PMB50T ¤0.14 Enhancement of Drug Absorption by PMB Copolymersmg/mL¥ or PMB100T ¤0.14 mg/mL¥ solution was higher than those in 0.1% Pluronic ¤0.06 mg/mL¥, 1% lecithin ¤0.08 mg/mL¥, 10% Gelucire ¤0.10 mg/mL¥, saline ¤0.05 mg/mL¥ and DW ¤0.05 mg/mL¥. Moreover, the solubility of GRF in 1% PMB50T ¤0.56 mg/mL¥ or PMB100T ¤0.55 mg/mL¥ solution was almost the same as that in 1% Polysorbate 60 ¤0.57 mg/mL¥, and higher than those in 10% Pluronic ¤0.25 mg/mL¥, 10% DMSO ¤0.30 mg/mL¥ 1% HCO60 ¤0.31 mg/mL¥ and 1% Ç-cyclodextrin solutions ¤0.24 mg/mL¥. In the case of 10% PMB50T ¤2.81 mg/mL¥ or PMB100T ¤2.85 mg/mL¥ solution, the solubility of GRF was much higher than in 10% Polysorbate solution ¤1.68 mg/mL¥.
Transcellular transport of GRF: Figure 3 shows the permeability for the apical to basolateral transport The LogP values were taken from the Drug Bank ¤http://www.drugbank.ca/¥. Fig. 3 . Effect of PMBs on GRF permeability across Caco-2 cell monolayers Permeability coefficients of GRF (300 µM) across Caco-2 cell monolayers were measured in the absence (control) and presence of each concentration of PMB50T or PMB100T at 37°C in HBSS at an apical-side pH 6.0 and at a basolateral-side pH of 7.4. Each column represents the mean ± SEM of three experiments. *Significantly different from the control (p < 0.05).
Fig. 2. Solubility of GRF with various solubilizers
of 300 µM GRF in the absence ¤control¥ or presence of 0.1, 1 or 10% PMBs by Caco-2 cells. The permeability coefficient of GRF in 0.1% PMB50T ¤0.49 + 0.12 ' 10 %6 cm/s¥ or PMB100T ¤0.47 + 0.084 ' 10 %6 cm/s¥ was the same as that of the control value ¤0.46 + 0.13 ' 10 %6 cm/s¥ ¤Fig. 3¥. The permeability coefficient of GRF in 1% PMB50T or PMB100T was reduced to 0.28 + 0.069 and 0.24 + 0.059 ' 10 %6 cm/s, respectively, compared with 0.1% PMB solutions. In the case of 10% PMB50T and PMB100T solutions, the permeability coefficients were further decreased to 0.097 + 0.001 and 0.12 + 0.009 ' 10 %6 cm/s, respectively.
Plasma concentrations of GRF in rats:
A photograph of GRF ¤2 mg/mL¥ in DW, 10% Gelucire, 10% PMB50T and PMB100T solutions is shown in Figure 4 . The plasma concentrations of GRF after a single oral administration of GRF ¤20 mg/10 mL/kg¥ in DW, 10% Gelucire, 10% PMB50T or PMB100T solution are shown in Figure 5 , and the pharmacokinetic parameters of GRF are summarized in Table 2 . GRF was completely dissolved in 10% PMB50T and PMB100T solutions, while it was suspended uniformly in 10% Gelucire, and GRF precipitates were observed in DW. Following oral administration of GRF in DW to rats, the plasma concentration of GRF reached a maximum of 0.42 µg/mL at 0.75 hours after administration, then declined slowly; the bioavailability ¤BA¥ was 14% and the C max /Dose ratio was 0.02. When GRF in 10% PMB50T solution was orally administered, the plasma concentration of GRF reached a maximum of 4.10 µg/mL at 0.67 hours with a BA of 54%, C max /Dose ratio of 0.21 and AUC/Dose ratio of 0.41. For GRF in 10% PMB100T solution, the plasma concentrations of GRF were comparable with those for GRF in 10% PMB50T solution. The BA, C max /Dose ratio and AUC/Dose ratio were 56%, 0.19 and 0.42, respectively. When GRF in 10% Gelucire suspension was orally administered, the plasma concentration of GRF increased slowly and reached a maximum of 1.02 µg/mL at 3.7 hours, with a BA of 32%, C max /Dose ratio of 0.05, and AUC/Dose ratio of 0.27.
Safety assessment of PMB in rats: In studies of repeated dose toxicity, no lesions in liver, kidney, small intestine or large intestine were observed ¤Fig. 6¥. Moreover, the levels of ALP, ALT, AST, BUN and CRE did not show any significant difference between the control and the 10% PMB50T or PMB100T solution-administered group ¤Table 3¥.
Discussion
MCZ ¤LogP value: 6.1¥ showed the highest solubility in PMB50T solution, followed by GRF ¤LogP value: 2.0¥ and Ara-A ¤LogP value: %2.1¥ ¤Table 1¥. It has been reported that PMB solutions dramatically enhance the water solubility of paclitaxel ¤LogP value: 3.0¥. 8¥ The relative solubilities of paclitaxel in the 0.1, 1.0, and 10% PMB solutions versus 10% DMSO solution were increased 580, 618 and 735 times, respectively ¤data from NOF Corporation¥. Because the increase of the solubility in PMB50T solution showed a positive correlation with LogP values, according to our data and previous reports, it appears that PMB50T is useful for enhancing the solubility of lipophilic compounds. For BCS class 2 compounds, enhancement of solubility improves oral absorption. On the other hand, increasing the solubility of class 4 compounds does not always lead to higher oral absorption because these drugs show low permeability as well as low solubility. GRF is often used as a model compound to evaluate solubilizing methodologies for oral administration of water-insoluble drugs.
17,21,22¥ Therefore, to Area under the plasma-concentration curve ¤AUC¥ from 0 to 8 hours after a single administration.
b AUC 0®W was calculated by adding AUC 0®8hr to AUC 8hr®W estimated using the elimination constant ¤ke¥. c Bioavailability. *Significantly different from rats given GRF dissolved in DW ¤p g 0.05¥. Enhancement of Drug Absorption by PMB Copolymersinvestigate whether PMB functions not only as a potent solubilizer but also as a drug permeability enhancer, we selected a class 4 drug, GRF, as a model compound. 10¥ The solubility of GRF was increased in proportion to the concentration of PMB50T or PMB100T. Especially, when GRF was dissolved in 10% PMB50T or PMB100T solution, Fig. 6 . Representative microscopic appearances of liver, kidney, small intestine and large intestine from rats orally administered with DW (A to D), 10% PMB50T (E to H), or 10% PMB100T (I to L) solution once daily for 14 successive days In A, E and I, centrilobular hepatocytes are seen. The asterisks indicate centrilobular veins. No abnormalities were seen in the hepatocytes. In B, F and J, glomeruli (indicated by arrowheads) and tubular epithelium in the kidneys showed no abnormalities. Also in the small intestine (C, G and K) or large intestine (D, H and L) , no abnormalities were remarked. H.E. staining. Bar: 50 µm. its solubility was dramatically higher than with any other tested aqueous solubilizers ¤Fig. 2¥. These results suggested that the solubilizing ability of the PMBs for water-insoluble compounds is superior to that of other commonly used aqueous solubilizers.
To investigate whether the PMB solutions function not only as solubilizers but also as permeability enhancers, we performed transport studies using Caco-2 cell monolayers ¤Fig. 3¥. Contrary to our expectations, the permeability coefficient decreased as the PMB concentration increased, suggesting that the PMB solutions work as solubilizers, not as permeability enhancers. The reason for this is not understood in detail. However, the release of GRF from PMBs might be blocked because interaction between GRF and PMBs could be strong and/or the solution might become viscous at higher concentrations of PMB.
GRF absorption in rats was greatly increased by oral administration of GRF in 10% PMB50T or 10% PMB100T solution compared with DW or 10% Gelucire suspension ¤Fig. 5, Table 2¥ . The C max and AUC of GRF in plasma obtained with PMB50T and PMB100T were higher than those with DW or 10% Gelucire suspension. There was not much difference in the absorption properties of GRF between PMB50T and PMB100T. T max of GRF with PMB50T or PMB100T was dramatically reduced compared with that for Gelucire suspension. It was suggested that GRF was completely dissolved in PMB50T and PMB100T solutions, and the absorption rate of GRF increased, whereas the absorption was solubility rate-limited owing to incomplete dissolution of GRF in Gelucire suspension. A number of absorption enhancement methodologies are available for oral water-insoluble drugs, including nonionic surfactant vesicles ¤niosomes¥, 19¥ oil-in-water submicron emulsion ¤o/w SE¥, 23¥ self-emulsifying drug delivery system ¤SEDDS¥, 17¥ spray-dried microparticles, 24¥ lipid coprecipitates 25¥ and liposomes. 22¥ GRF is often used as a standard to evaluate those methodologies. Systems containing surfactant and/or an oily phase usually afford higher GRF concentrations than those in PMB50T and PMB100T solutions, but the enhancement of absorption from the intestine was less than with our system. When GRF was orally administered to rats, the C max /Dose ratios of GRF in 10% PMB50T and PMB100T solutions ¤0.21 and 0.19¥ were greater than with any other reported methodology ¤Table 4¥. Further, the AUC/Dose ratios of GRF in PMB solutions were greater than those with the other systems, except SEDDS and niosomes. The solubilities of GRF in 10% PMB solutions were approximately 60 times higher than that in DW. On the other hand, permeabilities of GRF in 10% PMBs were 21®26% compared with that in DW. The solubility was counterbalanced by the permeability in this case. As a result, when GRF in 10% PMB solutions was administered to rats, bioavailability was approximately 3 times that when GRF in DW was used. These results suggested that PMBs are highly effective solubilizers for water-insoluble compounds.
We finally investigated the toxicity induced by repeated dosing of 10% PMB50T or PMB100T solution to rats. No profound injury in any organ was observed and no marked alteration was seen in plasma biomarker levels ¤Fig. 6, Table 3¥ . Other experiments, including Amesö test ¤mutagenicity¥, antigenicity, and acute toxicity tests in mice intravenously given PMB50T or PMB100T ¤data from NOF Corporation, http://www.nof-solubilizer.com/mpcð polymers.html¥ also supported the safety of these PMBs. Overall, the results suggest that PMBs are safe for living organisms.
In summary, our results indicate that PMB50T and PMB100T are effective and safe absorption enhancers for poorly soluble lipophilic drugs. The presumed mechanism of solubilization by PMBs was reported previously.
26¥
That is, it was suggested that the PMBs form a polymer aggregate in water through a hydrophobic interaction and maintain hydrophobic drugs inside polymer aggregates stably. It is not clear whether PMBs are absorbed concomitantly with drugs, and the mechanism through which PMB enhances oral drug absorption remains to be elucidated. Oil-water submicron emulsion.
c Self-emulsifying drug delivery system.
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